Monday, April 03, 2023 5:40:57 PM
A
The latest price target for Palisade Bio (NASDAQ: PALI) was reported by Maxim Group on March 30, 2023. The analyst firm set a price target for $50.00 expecting PALI to rise to within 12 months (a possible 2112.39% upside). 2 analyst firms have reported ratings in the last year.
Q
What is the most recent analyst rating for Palisade Bio (PALI)?
A
The latest analyst rating for Palisade Bio (NASDAQ: PALI) was provided by Maxim Group, and Palisade Bio upgraded their buy rating.
Q
When is the next analyst rating going to be posted or updated for Palisade Bio (PALI)?
A
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Palisade Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Palisade Bio was filed on March 30, 2023 so you should expect the next rating to be made available sometime around March 30, 2024.
Do not rely on my opinions when making investment decisions. They are only opinions and I am probably no smarter than you!
Recent PALI News
- Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) • GlobeNewswire Inc. • 05/01/2024 12:30:00 PM
- Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach • GlobeNewswire Inc. • 04/23/2024 12:30:00 PM
- Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool • GlobeNewswire Inc. • 04/16/2024 12:30:00 PM
- Palisade Bio to Participate in the Virtual Investor Lunch Break Event • GlobeNewswire Inc. • 04/11/2024 01:15:00 PM
- Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™ • GlobeNewswire Inc. • 04/10/2024 12:15:00 PM
- Palisade Bio Announces 1-for-15 Reverse Stock Split • GlobeNewswire Inc. • 04/03/2024 09:30:00 PM
- Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:35:16 PM
- Palisade Bio to Present at Digestive Disease Week (DDW) 2024 • GlobeNewswire Inc. • 02/15/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:54:03 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:10:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:38:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/13/2024 07:51:09 PM
- Palisade Bio Provides Corporate Update and Reiterates Guidance • GlobeNewswire Inc. • 02/13/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:03:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:38:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:37:40 PM
- Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members • GlobeNewswire Inc. • 02/08/2024 07:40:00 PM
- Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders • GlobeNewswire Inc. • 02/08/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:30:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM